Home » news »

Tumor-suppressing protein may be novel target in PAH therapy

 

ATS 2019, Dallas, TX — In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH), according to research presented at ATS 2019. Researchers found that a deficiency of this protein produced dysfunctional molecules unable to support cell structure and function, resulted in thickening of pulmonary blood vessels and led to PAH.

###

Session: A97 Station to Station: Unraveling the Molecular Pathogenesis of PAH

Abstract Presentation Time: Sunday, May 19, 2:45 p.m. CT

Location: Room C147, 148 and154 (Level 1), Kay Bailey Hutchison Convention Center Dallas

VIEW ABSTRACT

CONTACT FOR MEDIA

Yuanjun Shen, PhD

sheny@pitt.edu

 

Related Posts

  • No Related Posts